Abstract: The disclosure provides methods of treating an infection by a coronavirus with a fibroblast growth factor (“FGF”). Also provided herein are FGFs for treating an infection by a coronavirus and their use in the manufacture of a medicament for treating an infection by a coronavirus.

Abstract: The invention features contacting (in vitro or in vivo) a receptor-binding ligand with an organic molecule, which can be a small molecule (i.e., an organic molecule that is not a peptide), or a peptide that noncovalently binds to the ligand and either another ligand for the receptor (either a second copy of the first ligand, or a second, different ligand), the receptor itself, or both. Exemplary ligand/receptor pairs include FGF-2/FGF-R1 and EPO/EPO-R. The invention further features pharmaceutical compositions and methods of using such compositions for treating various medical conditions.

Abstract: The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion.

Abstract: The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion.

Abstract: Methods, kits and compositions for improving a subject's recovery from CNS injury are disclosed. In certain aspects, a method may include administering to a subject cells and a neural stimulant. Recovery may be manifest by improvements in sensorimotor or cognitive abilities, e.g., improved limb movement and control or improved speech capability. In certain embodiments, subject methods can be used as part of a treatment for damage resulting from ischemia, hypoxia or trauma.

Abstract: The invention features methods for treating a patient suffering from muscular dystrophy by administration of umbilical cord blood cells, e.g., by IV infusion.

Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.

Abstract: The present invention provides methods and compositions for treatment of mammals afflicted with an ischemic or traumatic injury of the central nervous system. The present invention capitalizes in part upon the discovery that administration of a morphogen to such a mammal provides significant improvement in central nervous system function, even when administered after central nervous system tissue has been damaged. The methods involve the administration of dimeric proteins defined as morphogens, inducers of these morphogens, or agonists of the corresponding morphogen receptors, or implantation of cells stimulated by exposure to the morphogens. The proteins defined as morphogens comprise a structurally and functionally distinct family within the TGF-&bgr; superfamily. Osteogenic protein-1 (OP-1) is considered to be an exemplary and preferred member of this morphogen family.

Abstract: The present invention relates to the treatment of central nervous system injuries by intracisternal or intravenous administration of polypeptide growth factors, such as basic fibroblast growth factor. This method provides significant benefits because administration can occur a substantial amount of time following an injury.

Abstract: The present invention relates to the treatment of central nervous system injuries by intracisternal or intravenous administration of polypeptide growth factors, such as basic fibroblast growth factor. This method provides significant benefits because administration can occur a substantial amount of time following an injury.

Abstract: The invention features apparatus and methods for measuring motor events of a subject, e.g., a human subject, where the motor events have a force component or both a frequency and force component. The apparatus include a transducer, adapted to generate an analog signal corresponding to frequency and/or force of the subject's motor event, e.g., a repetitive motion; an amplifier, which amplifies the analog signal; an analog-to-digital (A/D) converter, which converts the analog signal into a digital signal; and a computer. The computer is programmed to receive the digital signal as input, store the digital signal for subsequent retrieval, retrieve the stored digital signal for processing, and process the stored digital signal. The processing includes the measurement of mean force amongst the set of individual motor events over time and measurement of the mean frequency of the set of individual motor events over time.

Abstract: Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia, hypoxia, or neurodegeneration may result from stroke or cardiac arrest. This invention provides for the intravenous administration of neurotrophic factors such as bFGF, aFGF, NGF, CNTF, BDNF, NT3, NT4, IGF-I and IGF-II.